Press Releases May 11, 2026 04:05 PM

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Immunovant Announces Date for Q4 and Fiscal Year 2026 Financial Results and Business Update Conference Call

By Marcus Reed IMVT

Immunovant, a clinical-stage immunology company focused on autoimmune diseases, announced it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, via a webcast and conference call on May 20, 2026. The company will also provide a business update during the call.

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

IMVT

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Immunovant will release Q4 and full fiscal year 2026 financial results on May 20, 2026.
Company will provide a business update to investors during the webcast and conference call.
Immunovant focuses on developing anti-FcRn technology to address autoimmune diseases, impacting the biotechnology and pharmaceutical sectors.

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.

To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.

Contacts:

Investors

Keyur Parekh

[email protected]

Media

Stephanie Lee

[email protected]

Risks

As a clinical-stage company, Immunovant faces uncertainty regarding future drug approvals and commercial success, impacting biotech investors.
Financial results may reflect ongoing R&D expenses and operational costs without current product revenue, which could affect investor sentiment.
Market conditions and competitive pressures within the immunology and autoimmune disease treatment sectors could influence company performance.

Menu

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Key Points

Risks

More from Press Releases